Live News EQUITY FLASH L impact Nov 05, 2026, 04:20 AM UTC Ivonescimab Receives NMPA Priority Review Akeso said China’s NMPA granted priority review to ivonescimab for first-line biliary tract cancer. SquawkNews Desk